Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00816283 · ClinicalTrials.gov registry record · Phase 1
Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00816283 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 5 participants.
The verdict
NCT00816283, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
RATIONALE: Dasatinib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving dasatinib together with vorinostat may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of dasatinib when given together with vorinostat in treating patients with accelerated phase or blastic phase chronic myelogenous leukemia or acute lymphoblastic leukemia.
Interventions
- GENETIC gene expression analysis
- GENETIC mutation analysis
- DRUG dasatinib
- DRUG vorinostat
- GENETIC cytogenetic analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00816283
The ClinicalTrials.gov registry entry for NCT00816283 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00816283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00816283 about?
NCT00816283 is a clinical study titled "Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia". RATIONALE: Dasatinib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving dasatinib together with vorinostat may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of dasatinib when given togeth...
What is the current status of trial NCT00816283?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2008-09. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00816283?
The interventions under investigation include: gene expression analysis (GENETIC), mutation analysis (GENETIC), dasatinib (DRUG), vorinostat (DRUG), cytogenetic analysis (GENETIC).
Who is sponsoring clinical trial NCT00816283?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.